Clinical Psychiatry News - Rimonabant reduces CV risks in type 2 diabetes
Thursday, January 1st, 2009 SAN DIEGO — The investigational drug rimonabant produces highly significant cardiovascular and metabolic benefit in patients with type 2 diabetes, Andre Scheen, M.D., reported at the annual scientific sessions of the American Diabetes Association.
Earlier this year, Sanofi-Aventis filed for U.S. and European licensure of the selective endocannabinoid type 1–receptor blocker, based on data from a series of phase III trials involving more t…
